Caitlin Costello, MD

The panel explains their goals of treatment for older patients with transplant-ineligible multiple myeloma, and how they determine treatment duration.

Rafael Fonseca, MD, and Krina Patel, MD, discuss the standard treatment approaches for frail or elderly patients with transplant-ineligible multiple myeloma.

Dr Caitlin Costello presents the case of a patient with transplant-ineligible multiple myeloma and sparks a conversation on the available treatment regimens.

A look at how to measure an adequate treatment response in patients with transplant-ineligible newly-diagnosed multiple myeloma, and treatment regimens for high-risk patients.

Closing out their discussion, the panel highlights unmet needs in multiple myeloma that clinicians and patients still face.

Drs Cowan and Anderson review whether older agents such as isa-based regimens still have a place in R/R MM treatment after the introduction of bispecific agents and CAR-T therapy.

A panel of experts discusses whether all patients with multiple myeloma should undergo transplant, and how to select the optimal treatment regimens for the treatment of transplant-eligible newly-diagnosed multiple myeloma.

Amrita Krishnan, MD, presents the case of a 63-year-old woman with transplant-eligible newly-diagnosed multiple myeloma, and Caitlin Costello, MD, describes the design and outcomes of recent trials in the transplant eligible setting.

Dr Silbermann continues her discussion of BCMA-targeting agents with a look at data on the use of bispecific agents for R/R MM treatment after a patient has already received a BCMA therapy.

Key opinion leaders compare the overall benefits of CAR-T therapy and share some advice for managing the toxicities of CAR-T therapy as a patient transitions back to their local doctor.

Drs Sidana and Silbermann describe the currently available treatment options for early- and late-relapse MM, and how to select an appropriate regimen.

An explanation of the mechanism of action of bispecific antibodies and their use in relapsed/refractory multiple myeloma treatment.

Dr Caitlin Costello discusses how she adapts treatment to patients with transplant-ineligible NDMM based on fitness level, and why some patients receive doublet therapy.

Experts explain their approaches to maintenance therapy for patients with transplant-ineligible NDMM and when therapy should be reduced.

Dr Larry Anderson summarizes the study design and updated data of the MAIA trial, and Dr Rebecca Silbermann compares it against the SWOG 0777 trial.

Andrew Cowan, MD, presents the results of the ENDURANCE study comparing two triplet regimens in transplant-ineligible MM.

Caitlin Costello, MD, describes how to determine if a patient with MM is transplant-ineligible, and some factors to take into consideration when choosing a treatment regimen.

The panel explains their opinions on induction therapy approaches for high-risk and standard-risk patients with NDMM.

Dr Andrew Cowan describes how the appropriate duration of therapy for patients with transplant-eligible multiple myeloma, and Dr Caitlin Costello discusses her approach to maintenance therapy.

Larry Anderson, MD, explains the study design and outcomes of the DETERMINATION study, and sparks a discussion on which patients with NDMM should receive stem cell transplants.

Dr Rebecca Silbermann discusses the results of studies evaluating MRD-response adapted therapy in patients with transplant-eligible NDMM.

Surbhi Sidana, MD, and Caitlin Costello, MD, introduce the updated evidence regarding induction regimens for patients with transplant-eligible NDMM and how to select the appropriate induction regimen in this population.

A look at the unmet needs and future directions of multiple myeloma treatment.

Oncologists highlight novel agents currently being investigated for the treatment of relapsed/refractory multiple myeloma.

Key takeaways from the CARTITUDE-1 study and the KarMMA study evaluating CAR T-cell therapies for relapsed/refractory multiple myeloma.

An overview of BCMA-targeting bispecific agents in development for multiple myeloma, including talquetamab and teclistamab.

A panel of doctors discuss the available treatment options for early and late relapsed multiple myeloma, including approved novel BCMA-targeting agents.

A look at the patient outcomes with daratumumab use in the frontline vs second-line setting in patients with transplant-ineligible multiple myeloma, and the pros and cons of subcutaneous vs intravenous daratumumab.

A review of the available first-line treatment options for transplant-ineligible multiple myeloma, as well as the design and findings of the MAIA study.

Experts explain how to determine treatment duration and a successful response to induction therapy for transplant-eligible multiple myeloma.